These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1464625)

  • 21. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
    J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trinitrobenzoylated poly(D-lysine) as a stimulator of interactions between plasminogen, plasmin, and tissue-type plasminogen activator.
    Petersen LC; Suenson E
    Biochim Biophys Acta; 1986 Sep; 883(2):313-25. PubMed ID: 2943320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of omega-amino acids on plasminogen activation and fibrinolysis induced by staphylokinase.
    Levashov MY; Aisina RB; Gershkovich KB; Varfolomeyev SD
    Biochemistry (Mosc); 2007 Jul; 72(7):707-15. PubMed ID: 17680762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue-type plasminogen activator-mediated activation of plasminogen on the surface of group A, C, and G streptococci.
    Kuusela P; Ullberg M; Saksela O; Kronvall G
    Infect Immun; 1992 Jan; 60(1):196-201. PubMed ID: 1370273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The course and prerequisites of Lys-plasminogen formation during fibrinolysis.
    Suenson E; Thorsen S
    Biochemistry; 1988 Apr; 27(7):2435-43. PubMed ID: 3382632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo.
    Holvoet P; Lijnen HR; Collen D
    J Biol Chem; 1985 Oct; 260(22):12106-11. PubMed ID: 2413020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
    Ries M; Zenker M; Gaffney PJ
    Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma fibronectin enhances fibrinolytic system in vitro.
    Gilboa N; Kaplan JE
    Thromb Haemost; 1985 Oct; 54(3):639-44. PubMed ID: 2935966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity.
    Lucas MA; Straight DL; Fretto LJ; McKee PA
    J Biol Chem; 1983 Oct; 258(20):12171-7. PubMed ID: 6226655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
    Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activation by tissue plasminogen activator in the presence of stimulating CNBr fragment FCB-2 of fibrinogen is a two-phase reaction. Kinetic analysis of the initial phase of slow plasmin formation.
    Beckmann R; Geiger M; Binder BR
    J Biol Chem; 1988 May; 263(15):7176-80. PubMed ID: 2966802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease.
    Kim PY; Stewart RJ; Lipson SM; Nesheim ME
    J Thromb Haemost; 2007 Jun; 5(6):1250-6. PubMed ID: 17266698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skizzle is a novel plasminogen- and plasmin-binding protein from Streptococcus agalactiae that targets proteins of human fibrinolysis to promote plasmin generation.
    Wiles KG; Panizzi P; Kroh HK; Bock PE
    J Biol Chem; 2010 Jul; 285(27):21153-64. PubMed ID: 20435890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of staphylokinase concentration of plasminogen activation.
    Arai K; Mimuro J; Madoiwa S; Matsuda M; Sako T; Sakata Y
    Biochim Biophys Acta; 1995 Aug; 1245(1):69-75. PubMed ID: 7654768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.